Related references
Note: Only part of the references are listed.IL-12 Augments Antitumor Responses to Cycled Chemotherapy
Lingbing Zhang et al.
JOURNAL OF IMMUNOTHERAPY (2015)
Preexisting antitumor immunity augments the antitumor effects of chemotherapy
Lingbing Zhang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
IL-12 is required for anti-OX40-mediated CD4 T cell survival
Carl E. Ruby et al.
JOURNAL OF IMMUNOLOGY (2008)
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
Lionel Apetoh et al.
NATURE MEDICINE (2007)
The fate of effector CD8 T cells in vivo is controlled by the duration of antigen stimulation
Xiaopei Huang et al.
IMMUNOLOGY (2006)
Cutting edge:: IL-12 induces CD4+CD25- T cell activation in the presence of T regulatory cells
IL King et al.
JOURNAL OF IMMUNOLOGY (2005)
Cutting edge: Bcl-3 up-regulation by signal 3 cytokine (IL-12) prolongs survival of antigen-activated CD8 T cells
JO Valenzuela et al.
JOURNAL OF IMMUNOLOGY (2005)
Pre-existing tumor-sensitized T cells are essential for eradication of established tumors by IL-12 and cyclophosphamide plus IL-12
HN Le et al.
JOURNAL OF IMMUNOLOGY (2001)
Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma
S Ostrand-Rosenberg et al.
JOURNAL OF IMMUNOLOGY (2000)
Localization dose and time of antigens determine immune reactivity
RM Zinkernagel
SEMINARS IN IMMUNOLOGY (2000)
Share Paper
